CAROLYN STOLTE: Open Payments
NPI 1285241653 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,204 in 44 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $26 · 2025 $5,204
Consulting: $3,150Food & beverage: $1,458Travel & lodging: $510Education: $86
| Company | Payments | Amount |
|---|---|---|
| Eli Lilly and Company | 4 | $3,660 |
| UCB, Inc. | 4 | $226 |
| Regeneron Healthcare Solutions, Inc. | 7 | $214 |
| Galderma Laboratories, L.P. | 6 | $210 |
| ABBVIE INC. | 4 | $202 |
| GENZYME CORPORATION | 3 | $184 |
| Amgen Inc. | 3 | $122 |
| Novartis Pharmaceuticals Corporation | 2 | $113 |
| Organon LLC | 1 | $73 |
| Lilly USA, LLC | 2 | $45 |
Products named: EBGLYSS, DUPIXENT, NEMLUVIO, OTEZLA, RINVOQ, Bimzelx, Rhapsido, SKYRIZI.
Industry payments across MD — which companies pay providers there.
